| List of Principal Contributors | p. ix |
| Preface | p. xiii |
| Immunopathogenesis and Liver Diseases: Basic Principles | |
| The liver as an immune organ | p. 3 |
| Immunogenetics of liver disease | p. 8 |
| Lipotoxicity and apoptosis in non-alcoholic fatty liver disease | p. 30 |
| Fibrogenesis, hepatic stellate cells and the immune system | p. 36 |
| Molecular characterization of autoantigens in autoimmune liver diseases | p. 42 |
| Immune mechanisms of viral clearance and pathogenesis of hepatitis C | p. 57 |
| Immune aspects of pathogenesis of alcoholic liver disease | p. 72 |
| Aetiology of primary biliary cirrhosis | p. 78 |
| Autoimmune hepatitis and overlap syndromes | p. 92 |
| Immunopathogenesis and Liver Diseases: Clinical Implications | |
| Primary sclerosing cholangitis | p. 111 |
| Immunological mechanisms of liver allograft rejection | p. 122 |
| Recurrence of autoimmune liver disease after liver transplantation | p. 128 |
| Human hepatic stem cells - potential for the future | p. 144 |
| Mucosal immunity, intestinal microflora and inflammatory bowel disease | p. 152 |
| Immunopathological Mechanisms of Gut Inflammation | |
| Genes and immunopathology | p. 171 |
| Defensins, innate immunity and the pathogenesis of inflammatory bowel disease | p. 172 |
| Progress of knowledge of immunopathogenesis in coeliac disease | p. 178 |
| Impact of immunodeficiency on immunological homeostasis in the gut | p. 180 |
| Immunopathology of the Gut: Clinical Aspects | |
| Pathological versus clinical differential diagnosis in inflammatory bowel disease | p. 213 |
| Refractory sprue - what it is and what to do | p. 215 |
| Collagenous and lymphocytic colitis: distinct disorders or part of the spectrum of inflammatory bowel disease? | p. 219 |
| Predictive factors of the course and therapeutic response in inflammatory bowel disease | p. 234 |
| Therapeutic Consequences of Immunopathological Processes in Inflammatory Bowel Disease | |
| Efficacy and limits of immunomodulators in inflammatory bowel disease: azathioprine, 6-mercaptopurine, methotrexate and mycophenolate mofetil | p. 249 |
| Does 6-thioguanine therapy represent a new promising therapeutic modality? | p. 261 |
| Anti-tumour necrosis factor therapy in clinical practice: what is advance and what is not? | p. 267 |
| New possibilities in anticytokine therapy for inflammatory bowel disease | p. 271 |
| Medical therapy of inflammatory bowel disease: current state and perspectives in the future | p. 280 |
| Index | p. 299 |
| Table of Contents provided by Rittenhouse. All Rights Reserved. |